Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Whegang, Solange Youdom ^a,b,c   Tahar, Rachida ^a   Foumane, Vincent Ngane ^a   Soula, Georges ^d   Gwét, Henri ^b   Thalabard, Jean Christophe ^c   Basco, Leonardo K ^a  

^a Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; AMODIAQUINE PLUS FANSIDAR; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ARTESUNATE PLUS FANSIDAR; ARTESUNATE PLUS MEFLOQUINE; CHLORPROGUANIL PLUS DAPSONE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUO COTECXIN; FANSIDAR; MEFLOQUINE; PARACETAMOL; UNCLASSIFIED DRUG; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ARTICLE; CAMEROON; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; OUTCOME ASSESSMENT; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG MONITORING; FOLLOW UP; ISOLATION AND PURIFICATION; NEWBORN; ORAL DRUG ADMINISTRATION; PARASITOLOGY; REGRESSION ANALYSIS; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CAMEROON; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; REGRESSION ANALYSIS; SULFADOXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649300670     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-56     Document Type: Article

References (33)

1. World Health Organization, Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996-2004 Geneva: World Health Organization 2005 WHO/HTM/MAL/2005.1103
2. The prevention of antimalarial drug resistance. W Peters, Pharmacol Ther 1990 47 499 508
3. World Health Organization, Antimalarial drug combination therapy. Report of a WHO technical consultation Geneva: World Health Organization, 2001 2001 WHO/CDS/RBM/2001.35
4. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. LK Basco V Foumane Ngane M Ndounga A Same-Ekobo JC Youmba RT Okalla Abodo G Soula, Am J Trop Med Hyg 2006 75 388 395
5. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated Plasmodium falciparum malaria in young children in Cameroon. LK Basco A Same-Ekobo V Foumane Ngane M Ndounga T Metoh P Ringwald G Soula, Bull World Health Organ 2002 80 538 545
6. World Health Organization, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria Geneva: World Health Organization 2003 WHO/HTM/RBM/2003.50
7. World Health Organization, Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission Geneva: World Health Organization 1996 WHO/MAL/96.1077
8. World Health Organization, Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations Geneva: World Health Organization 2008
9. Beta blockade during and after myocardial infarction: an overview of the randomized trials. S Yusuf R Peto J Lewis R Collins P Sleight, Prog Cardiovasc Dis 1985 27 335 371
10. Random-effects model for meta-analysis of clinical trials: an update. R DerSimonian R Kacker, Contemp Clin Trial 2007 28 105 114
11. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. FH Jansen E Lesaffre LK Penali MJ Garcia Zattera H Die-Kakou E Bissagnene, Am J Trop Med Hyg 2007 77 1005 1009
12. The Comprehensive R Archive Network (CRAN). http://www.cran.r-project. org/
13. WinBUGS version 1.4 User manual. MRC Biostatistics Unit, UK. D Spiegelhalter A Thomas N Best DJ Lunn, 2003 http://www.mrc-bsu.cam.ac.uk/bugs/ winbugs/contents.shtml
14. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. DG Altman KF Schulz D Moher M Egger F Davidoff D Elbourne PC Gotzsche T Lang, Ann Intern Med 2001 134 663 694
15. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. RD Newman ME Parise L Slutsker B Nahlen RW Steketee, Trop Med Int Health 2003 8 488 506
16. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. J Hwang E Bitarakwate M Pai A Reingold PJ Rosenthal G Dorsey, Trop Med Int Health 2006 11 789 799
17. Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: A meta-analysis. CO Obonyo EA Juma BR Ogutu JM Vulule J Lau, Trans R Soc Trop Med Hyg 2007 101 117 126
18. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. M Adjuik P Agnamey A Babiker S Borrmann P Brasseur M Cisse F Cobelens S Diallo JF Faucher P Garner S Gikunda PG Kremsner S Krishna B Lell M Loolpapit PB Matsiegui MA Missinou J Mwanza F Ntoumi P Olliaro P Osimbo P Rezbach E Some WRJ Taylor, Lancet 2002 359 1365 1372
19. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. L von Seidlein P Milligan M Pinder K Bojang C Anyalebechi R Gosling R Coleman JI Ude A Sadiq M Duraisingh D Warhurst A Alloueche G Targett K McAdam B Greenwood G Walraven P Olliaro T Doherty, Lancet 2000 355 352 7
20. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. T Mutabingwa A Nzila E Mberu E Nduati P Winstanley E Hills W Watkins, Lancet 2001 358 1218 1223
21. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. JG Kublin FK Dzinjalamala DD Kamwendo EM Malkin JF Cortese LM Martino RAG Mukadam SJ Rogerson AG Lescano ME Molyneux PA Winstanley P Chimpeni TE Taylor CV Plowe, J Infect Dis 2002 185 380 388
22. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. A Alloueche W Bailey S Barton J Bwika P Chimpeni CO Falade FA Fehintola J Horton S Jaffar T Kanyok PG Kremsner JG Kublin T Lang MA Missinou C Mkandala AMJ Oduola Z Premji L Robertson A Sowunmi SA Ward PA Winstanley, Lancet 2004 363 1843 1848 10.1016/S0140-6736(04)16350-2 15183620
23. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. RN Price F Nosten C Luxemburger M van Vugt L Phaipun T Chongsuphajaisiddhi NJ White, Trans R Soc Trop Med Hyg 1997 91 574 577
24. Artesunate with mefloquine at various intervals for non-severe Plasmodium falciparum malaria. LQ Hung PJ de Vries TQ Binh PT Giao NV Nam R Holman PA Kager, Am J Trop Med Hyg 2004 71 160 166
25. Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens. F Smithuis I van der Broek N Katterman M Kyaw Kyaw A Brockman S Lwin NJ White, Trans R Soc Trop Med Hyg 2004 98 182 192
26. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. S Vijaykadga C Rojanawatsirivej S Cholpol D Phoungmanee A Nakavej C Wongsrichanalai, Trop Med Int Health 2006 11 211 219
27. A randomized, double-blind study on the efficacy and safety of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. A Massougbodji M Kone D Kinde-Gazard A Same-Ekobo N Cambon EA Mueller, Trans R Soc Trop Med Hyg 2002 96 655 659
28. Efficacy and safety of an artesunate/mefloquine combination (Artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya. KM Bhatt BM Samia SM Bhatt KM Wasunna, East Afr Med J 2006 83 236 242
29. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. FO Ter Kuile F Nosten C Luxemburger D Kyle P Teja-Isavatharm L Phaipun R Price T Chongsuphajaisiddhi NJ White, Bull World Health Organ 1995 73 631 642
30. Piperaquine. A resurgent antimalarial drug. TME Davis TY Hung IK Sim HA Karunajeewa KF Ilett, Drugs 2005 65 75 87
31. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. MB Denis TME Davis S Hewitt S Incardona K Nimol T Fandeur Y Poravuth C Lim D Socheat, Clin Infect Dis 2002 35 1469 1476
32. Randomized, controlled dose-optimization studies of dihydroartemisinin- piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. EA Ashley S Krudsood L Phaiphun S Srivilairit R McGready W Leowattana R Hutagalung P Wilairatana A Brockman S Looareesuwan F Nosten NJ White, J Infect Dis 2004 190 1773 1782
33. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. F Smithuis M Kyaw Kyaw O Phe K Zarli Aye L Htet M Barends N Lindegardh T Singtoroj E Ashley S Lwin K Stepniewska NJ White, Lancet 2006 367 2075 2085